AR063257A1 - Anticuerpos anti-linfotoxina alfa - Google Patents
Anticuerpos anti-linfotoxina alfaInfo
- Publication number
- AR063257A1 AR063257A1 ARP070104513A ARP070104513A AR063257A1 AR 063257 A1 AR063257 A1 AR 063257A1 AR P070104513 A ARP070104513 A AR P070104513A AR P070104513 A ARP070104513 A AR P070104513A AR 063257 A1 AR063257 A1 AR 063257A1
- Authority
- AR
- Argentina
- Prior art keywords
- sequence identifier
- sequence
- amino acids
- cdr
- identifier
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C07K16/242—Lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q99/00—Subject matter not provided for in other groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Business, Economics & Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
Abstract
Métodos para preparar dichos anticuerpos, composiciones y artículos que incorporan esos anticuerpos y sus usos en el tratamiento de una enfermedad autoinmune, entre otras. Los anticuerpos incluyen anticuerpos murinos, quiméricos y humanizados. Reivindicacion 1: Un anticuerpo anti-linfotoxina-alfa (LTalfa) aislado que comprende al menos una secuencia de la region de determinacion de complementariedad (CDR) del grupo formado por: (a) Una secuencia CDR-L 1 que comprende aminoácidos A1-A11, donde A1-A11 es KASQAVSSAVA (identificador de secuencia n°:1) o RASQAVSSAVA (identificador de secuencia n°: 2), o comprende aminoácidos A1-A17, donde A1-A17 es KSSQSLLYSTNQKNFLA (identificador de secuencia n°: 3) o KSSQSLLYSANQKNFLA (identificador de secuencia n°: 4) o KSSQSLLYSTNQKNALA (identificador de secuencia n°: 6), donde N es cualquier aminoácido; (b) una secuencia CDR-L2 que comprende aminoácidos B1-B7, donde B1 -B7 es SASHIRYT (identificador de secuencia n°:7) o WASTRDS (identificador de secuencia n°:8), (c) una secuencia CDR-L3 que comprende aminoácidos C1-C9, donde C1-C9 es QQHYSTPWT (identificador de secuencia n°: 9) o QENYSTPWT (identificador de secuencia n° 11) o QQYYSYPRT (identificador de secuencia n°: 13) o QQYASYPRT (identificador de secuencia n°: 14) o QQYYAYPRT (identificador de secuencia n°: 15), donde N es cualquier aminoácido, (d) una secuencia CDR-H1 que comprende aminoácidos D1-D10, donde D1-D10 es GYTFTSYVIH (identificador de secuencia n°: 16) o GYTFSSYWIE (identificador de secuencia n°: 17), (e) una secuencia CDR-H2 que comprende aminoácidos E1-E17, donde E1-E17 es YNNPYNDGTNYNEKFKG (identificador de secuencia n°: 18) o EISPGSGSTNYNEEFKG (identificador de secuencia n°: 19) o YNNPYNAGTNYNEKFKG (identificador de secuencia n°: 101) o EINPGSGSTIYNEKFKG (identificador de secuencia n°: 110), donde N es cualquier aminoácido; y (f) una secuencia CDR-H3 que comprende aminoácidos F1-F9, donde F1-F9 es PTMLPWFAY (identificador de secuencia n°:20), o comprende aminoácidos F1-F5, donde F1-F5 es GYHGY (identificador de secuencia nö:21) o GYHGA (identificador de secuencia n°: 22).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82925706P | 2006-10-12 | 2006-10-12 | |
US93899907P | 2007-05-18 | 2007-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063257A1 true AR063257A1 (es) | 2009-01-14 |
Family
ID=39430415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104513A AR063257A1 (es) | 2006-10-12 | 2007-10-11 | Anticuerpos anti-linfotoxina alfa |
Country Status (21)
Country | Link |
---|---|
US (4) | US7923011B2 (es) |
EP (1) | EP2084188A2 (es) |
JP (1) | JP5298021B2 (es) |
KR (1) | KR20090078349A (es) |
AR (1) | AR063257A1 (es) |
AU (1) | AU2007324135B2 (es) |
BR (1) | BRPI0715580A2 (es) |
CA (1) | CA2665644A1 (es) |
CL (1) | CL2007002926A1 (es) |
CO (1) | CO6220841A2 (es) |
CR (1) | CR10705A (es) |
IL (1) | IL197937A0 (es) |
MA (1) | MA30876B1 (es) |
MX (1) | MX2009003774A (es) |
NO (1) | NO20091841L (es) |
NZ (1) | NZ576032A (es) |
PE (1) | PE20080980A1 (es) |
RU (1) | RU2486201C2 (es) |
TW (1) | TWI414531B (es) |
UA (1) | UA94484C2 (es) |
WO (1) | WO2008063776A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110084196A (ko) * | 2008-09-26 | 2011-07-21 | 유레카 쎄라퓨틱스, 인코포레이티드 | 다양한 글리코실화 패턴을 가진 세포계 및 단백질 |
CN102224421A (zh) * | 2008-09-30 | 2011-10-19 | 弗·哈夫曼-拉罗切有限公司 | 预测应答淋巴毒素拮抗剂的类风湿性关节炎的生物学标记 |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
WO2011060015A1 (en) | 2009-11-11 | 2011-05-19 | Genentech, Inc. | Methods and compositions for detecting target proteins |
RU2012147249A (ru) | 2010-04-07 | 2014-05-20 | Эббви Инк. | TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ |
US8858944B2 (en) | 2010-06-02 | 2014-10-14 | Sumitomo Dainippon Pharma Co., Ltd. | Treatment drug for autoimmune diseases and allergic diseases |
CN102621310B (zh) * | 2011-01-28 | 2014-07-02 | 上海科新生物技术股份有限公司 | 胶体金层析法抗u1-rnp抗体检测试纸及其制备方法 |
KR20130036993A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | c-Met의 SEMA 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
WO2013114164A1 (en) * | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Method for obtaining glycoprotein composition with increased afucosylation content |
TW201400132A (zh) | 2012-05-21 | 2014-01-01 | Genentech Inc | 改善血腦屏障運送之安全性之方法 |
GB201314052D0 (en) | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
CN105829543B (zh) * | 2013-10-14 | 2021-06-01 | 西纳福克斯股份有限公司 | 糖基改造的抗体、抗体-缀合物及其制备方法 |
WO2015057906A1 (en) * | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
KR101820572B1 (ko) * | 2015-08-12 | 2018-01-19 | 가톨릭대학교 산학협력단 | 만성골수성백혈병에 관한 정보 제공 방법 |
PL3371206T3 (pl) * | 2015-11-02 | 2021-09-27 | F. Hoffmann-La Roche Ag | Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka |
CN112153983A (zh) * | 2018-05-23 | 2020-12-29 | 杰克逊实验室 | 抗ngly-1抗体及使用方法 |
CN111285936A (zh) * | 2020-03-11 | 2020-06-16 | 北京双赢科创生物科技有限公司 | 靶向肿瘤的酸性敏感纳米肽段及其应用 |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4920196A (en) | 1982-07-30 | 1990-04-24 | Genentech, Inc. | Human lymphotoxin |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4959457A (en) | 1984-05-31 | 1990-09-25 | Genentech, Inc. | Anti-lymphotoxin |
US5683688A (en) | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
NZ212207A (en) * | 1984-05-31 | 1991-07-26 | Genentech Inc | Recombinant lymphotoxin |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
JP2755395B2 (ja) | 1987-09-23 | 1998-05-20 | ブリストル―マイアーズ スクイブ コムパニー | Hiv感染細胞に殺作用する抗体異種結合体 |
JPH023698A (ja) | 1988-06-20 | 1990-01-09 | Denki Kagaku Kogyo Kk | ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US6475787B1 (en) | 1989-07-28 | 2002-11-05 | Wyeth | Method for producing monoclonal antibodies |
NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US7030080B2 (en) | 1990-06-27 | 2006-04-18 | Biogen, Inc. | Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof |
WO1992000329A1 (en) | 1990-06-27 | 1992-01-09 | Biogen, Inc. | Surface complexed lymphotoxin |
US5795964A (en) | 1990-06-27 | 1998-08-18 | Biogen, Inc. | Lymphotoxin-beta and lymphotoxin-beta complexes |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
RU2048521C1 (ru) * | 1992-05-25 | 1995-11-20 | Научно-Исследовательский Конструкторско-Технологический Институт Биологически Активных Веществ | Способ получения полипептида со свойствами лимфотоксина человека |
US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US20050255104A1 (en) | 1993-01-29 | 2005-11-17 | Centocor, Inc. | Methods of treating psoriasis using anti-TNF receptor fusion proteins |
US5747023A (en) | 1994-07-01 | 1998-05-05 | Genentech, Inc. | Cancer therapy using lymphotoxin |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6027888A (en) | 1996-04-05 | 2000-02-22 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
US5747373A (en) * | 1996-09-24 | 1998-05-05 | Taiwan Semiconductor Manufacturing Company Ltd. | Nitride-oxide sidewall spacer for salicide formation |
IL129527A (en) | 1996-10-25 | 2006-12-10 | Biogen Idec Inc | Pharmaceutical preparations containing soluble lymphoxine-beta receptors |
US7255854B1 (en) | 1996-10-25 | 2007-08-14 | Biogen, Inc. | Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
WO2000006708A1 (fr) * | 1998-07-29 | 2000-02-10 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau polypeptide |
TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR100940380B1 (ko) * | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
DE60045240D1 (de) | 1999-03-02 | 2010-12-30 | Centocor Inc | Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
US7056695B2 (en) | 2000-03-02 | 2006-06-06 | Xencor | TNF-α variants |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
AU6842701A (en) | 2000-06-16 | 2002-01-14 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
US20060034830A1 (en) | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform |
AU7684201A (en) | 2000-06-28 | 2002-01-08 | Glycofi Inc | Methods for producing modified glycoproteins |
US20060029604A1 (en) | 2000-06-28 | 2006-02-09 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US20060034828A1 (en) | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
WO2002030986A2 (en) | 2000-10-13 | 2002-04-18 | Biogen, Inc. | HUMANIZED ANTI-LT-β-R ANTIBODIES |
IL156618A0 (en) | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
US20050271663A1 (en) | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US20040038349A1 (en) | 2001-07-27 | 2004-02-26 | Hilbert David M. | Heteromultimeric TNF ligand family members |
CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
WO2003047510A2 (en) | 2001-11-30 | 2003-06-12 | Centocor, Inc. | Anti-tnf antibodies, compositions, methods and uses |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003215130A1 (en) * | 2002-02-08 | 2003-09-02 | Wyeth | Composition and method for modulating an inflammatory response |
AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
CA2481401A1 (en) | 2002-04-15 | 2003-10-30 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
NZ537965A (en) | 2002-07-01 | 2008-04-30 | Biogen Idec Inc | Humanized anti-lymphotoxin beta receptor antibodies |
US6873910B2 (en) * | 2002-10-22 | 2005-03-29 | Qualcomm Incorporated | Procedure for searching for position determination signals using a plurality of search modes |
JP2006504775A (ja) | 2002-10-31 | 2006-02-09 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | リンホトキシン経路インヒビターによる免疫学的腎障害の処置 |
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
BR0317573A (pt) | 2002-12-20 | 2005-11-22 | Biogen Idec Inc | Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos |
JP4464395B2 (ja) | 2003-03-05 | 2010-05-19 | ヘイローザイム インコーポレイテッド | 可溶性ヒアルロニダーゼ糖タンパク質(sHASEGP)、その調製プロセス、使用およびそれを含む薬学的組成物 |
NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
RS58420B1 (sr) | 2003-11-05 | 2019-04-30 | Roche Glycart Ag | Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom |
KR100772800B1 (ko) | 2003-11-17 | 2007-11-01 | 주식회사유한양행 | 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자 |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
US20050266004A1 (en) | 2003-12-08 | 2005-12-01 | Jill Giles-Komar | Anti-human lymphotoxin alpha antibodies, compositions, methods and uses |
WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
JP2008515772A (ja) | 2004-07-21 | 2008-05-15 | グライコフィ, インコーポレイテッド | Gal2GlcNAc2Man3GlcNAc2グリコフォームを支配的に含む免疫グロブリン |
JP2008507535A (ja) | 2004-07-21 | 2008-03-13 | グライコフィ, インコーポレイテッド | 主にman5glcnac2グリコフォームを含むイムノグロブリン |
CA2573745A1 (en) | 2004-07-21 | 2007-01-12 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
EP1771480A1 (en) | 2004-07-21 | 2007-04-11 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man3glcnac2 glycoform |
AU2005269712A1 (en) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulins comprising predominantly a GlcNAcMan5GlcNAc2 glycoform |
KR20080080675A (ko) | 2004-08-19 | 2008-09-04 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
JP2006228261A (ja) | 2005-02-15 | 2006-08-31 | Micron Technology Inc | デジット線絶縁ゲートの負電圧駆動 |
CA2605781A1 (en) | 2005-05-09 | 2007-04-12 | Glycart Biotechnology Ag | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
-
2007
- 2007-10-11 TW TW096138038A patent/TWI414531B/zh not_active IP Right Cessation
- 2007-10-11 JP JP2009532587A patent/JP5298021B2/ja not_active Expired - Fee Related
- 2007-10-11 EP EP07871155A patent/EP2084188A2/en not_active Withdrawn
- 2007-10-11 US US11/871,136 patent/US7923011B2/en not_active Expired - Fee Related
- 2007-10-11 BR BRPI0715580-8A2A patent/BRPI0715580A2/pt not_active IP Right Cessation
- 2007-10-11 MX MX2009003774A patent/MX2009003774A/es active IP Right Grant
- 2007-10-11 CA CA002665644A patent/CA2665644A1/en not_active Abandoned
- 2007-10-11 NZ NZ576032A patent/NZ576032A/en not_active IP Right Cessation
- 2007-10-11 RU RU2009117680/10A patent/RU2486201C2/ru not_active IP Right Cessation
- 2007-10-11 WO PCT/US2007/081154 patent/WO2008063776A2/en active Application Filing
- 2007-10-11 AU AU2007324135A patent/AU2007324135B2/en not_active Ceased
- 2007-10-11 AR ARP070104513A patent/AR063257A1/es not_active Application Discontinuation
- 2007-10-11 UA UAA200904634A patent/UA94484C2/uk unknown
- 2007-10-11 CL CL200702926A patent/CL2007002926A1/es unknown
- 2007-10-11 PE PE2007001374A patent/PE20080980A1/es not_active Application Discontinuation
- 2007-10-11 KR KR1020097009641A patent/KR20090078349A/ko not_active Application Discontinuation
-
2009
- 2009-04-03 CR CR10705A patent/CR10705A/es unknown
- 2009-04-05 IL IL197937A patent/IL197937A0/en unknown
- 2009-05-08 MA MA31855A patent/MA30876B1/fr unknown
- 2009-05-11 NO NO20091841A patent/NO20091841L/no not_active Application Discontinuation
- 2009-05-12 CO CO09048130A patent/CO6220841A2/es active IP Right Grant
-
2011
- 2011-02-11 US US13/026,069 patent/US8216807B2/en not_active Expired - Fee Related
- 2011-02-11 US US13/026,123 patent/US8541552B2/en not_active Expired - Fee Related
-
2012
- 2012-07-06 US US13/543,485 patent/US8642740B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
BRPI0715580A2 (pt) | 2014-06-10 |
NO20091841L (no) | 2009-07-13 |
UA94484C2 (uk) | 2011-05-10 |
EP2084188A2 (en) | 2009-08-05 |
TWI414531B (zh) | 2013-11-11 |
PE20080980A1 (es) | 2008-09-02 |
US8541552B2 (en) | 2013-09-24 |
NZ576032A (en) | 2012-03-30 |
WO2008063776A3 (en) | 2009-03-05 |
CA2665644A1 (en) | 2008-05-29 |
JP2010506568A (ja) | 2010-03-04 |
CR10705A (es) | 2009-05-07 |
RU2009117680A (ru) | 2010-11-20 |
MA30876B1 (fr) | 2009-11-02 |
AU2007324135B2 (en) | 2013-06-27 |
TW200825101A (en) | 2008-06-16 |
US7923011B2 (en) | 2011-04-12 |
US8216807B2 (en) | 2012-07-10 |
US20090285830A1 (en) | 2009-11-19 |
US20130011412A1 (en) | 2013-01-10 |
JP5298021B2 (ja) | 2013-09-25 |
AU2007324135A1 (en) | 2008-05-29 |
US20110150865A1 (en) | 2011-06-23 |
US8642740B2 (en) | 2014-02-04 |
CL2007002926A1 (es) | 2008-05-16 |
WO2008063776A2 (en) | 2008-05-29 |
KR20090078349A (ko) | 2009-07-17 |
RU2486201C2 (ru) | 2013-06-27 |
IL197937A0 (en) | 2011-08-01 |
MX2009003774A (es) | 2009-04-22 |
US20110208673A1 (en) | 2011-08-25 |
CO6220841A2 (es) | 2010-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063257A1 (es) | Anticuerpos anti-linfotoxina alfa | |
PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
RS52919B (en) | SCLEROSTINE BINDING AGENTS | |
CO2018004532A2 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
CO5631451A2 (es) | Anticuerpo especifico para cd22 humano y composicion farmaceutica derivada | |
AR080243A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
RS54452B1 (en) | INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
NZ585559A (en) | Humanized antibodies against tl1a | |
AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
UA108466C2 (en) | Antibody antagonises c-Met | |
CO6180454A2 (es) | Anticuerpos de la egfl7 y metodos de uso | |
PE20040947A1 (es) | MOLECULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA | |
JP2018507220A5 (es) | ||
AR075925A1 (es) | Anticuerpos anti-alfa5beta1 (alfa5beta1: glicoproteina integrina) y sus usos | |
RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
NZ605980A (en) | Anti-fap antibodies and methods of use | |
AR067543A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso | |
RS54197B1 (en) | NEW ANTIBODIES FOR THE INHIBITION OF C-MET DIMERIZATION AND THEIR USE | |
PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
NZ596712A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
NZ596837A (en) | Anti-vegf antibodies and their uses | |
AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
JP2010022372A5 (es) | ||
ES2721753T3 (es) | Anticuerpos contra IL-6 y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |